158 related articles for article (PubMed ID: 31532472)
1. Treatment of Refractory Chronic Pruritus of Unknown Origin With Tofacitinib in Patients With Rheumatoid Arthritis.
Wang F; Morris C; Bodet ND; Kim BS
JAMA Dermatol; 2019 Dec; 155(12):1426-1428. PubMed ID: 31532472
[No Abstract] [Full Text] [Related]
2. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
[TBL] [Abstract][Full Text] [Related]
4. A case of rheumatoid arthritis with multiple lung rheumatoid nodules successfully treated with tofacitinib.
Kondo M; Murakawa Y; Honda M; Yanagawa T; Nagasaki M; Moriyama M; Watanabe Y; Kakimaru H
Mod Rheumatol Case Rep; 2021 Jan; 5(1):1-5. PubMed ID: 33269655
[TBL] [Abstract][Full Text] [Related]
5. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Schulze-Koops H; Strand V; Nduaka C; DeMasi R; Wallenstein G; Kwok K; Wang L
Rheumatology (Oxford); 2017 Jan; 56(1):46-57. PubMed ID: 28028154
[TBL] [Abstract][Full Text] [Related]
6. [Tofacitinib].
Döker S; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
[TBL] [Abstract][Full Text] [Related]
7. Two cases of rheumatoid arthritis complicated by organising pneumonia successfully treated with tofacitinib therapy.
Kodera T; Tsutsumi T; Oka Y; Takeda T; Shirota Y; Kameoka J
Mod Rheumatol Case Rep; 2021 Jul; 5(2):218-225. PubMed ID: 33784938
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
9. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Feldman SR; Thaçi D; Gooderham M; Augustin M; de la Cruz C; Mallbris L; Buonanno M; Tatulych S; Kaur M; Lan S; Valdez H; Mamolo C
J Am Acad Dermatol; 2016 Dec; 75(6):1162-1170.e3. PubMed ID: 27692733
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
[No Abstract] [Full Text] [Related]
15. Tofacitinib for treatment of rheumatoid arthritis.
Rakieh C; Conaghan PG
Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
[TBL] [Abstract][Full Text] [Related]
17. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
Bushmakin AG; Mamolo C; Cappelleri JC; Stewart M
J Dermatolog Treat; 2015 Feb; 26(1):19-22. PubMed ID: 24289224
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of rheumatoid neutrophilic panniculitis with tofacitinib.
Almeida Junior HL; Furtado VD; Issaacson VS; Boff AL
An Bras Dermatol; 2024; 99(4):644-647. PubMed ID: 38658238
[No Abstract] [Full Text] [Related]
19. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
20. Varicella zoster virus myelitis in a patient with rheumatoid arthritis treated by tofacitinib.
Itamiya T; Komai T; Tsuchida Y; Shoda H; Fujio K
Scand J Rheumatol; 2021 Jul; 50(4):319-321. PubMed ID: 32940139
[No Abstract] [Full Text] [Related]
[Next] [New Search]
